Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Interleukin-10 is a protective factor against diet-induced insulin resistance in liver.

Cintra DE, Pauli JR, Araújo EP, Moraes JC, de Souza CT, Milanski M, Morari J, Gambero A, Saad MJ, Velloso LA.

J Hepatol. 2008 Apr;48(4):628-37. doi: 10.1016/j.jhep.2007.12.017. Epub 2008 Jan 31.

PMID:
18267346
2.

The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice.

Pinto Lde F, Compri CM, Fornari JV, Bartchewsky W, Cintra DE, Trevisan M, Carvalho Pde O, Ribeiro ML, Velloso LA, Saad MJ, Pedrazzoli J Jr, Gambero A.

Liver Int. 2010 Apr;30(4):603-10. doi: 10.1111/j.1478-3231.2009.02200.x. Epub 2010 Jan 15.

PMID:
20088867
3.

Subtle metabolic and liver gene transcriptional changes underlie diet-induced fatty liver susceptibility in insulin-resistant mice.

Toye AA, Dumas ME, Blancher C, Rothwell AR, Fearnside JF, Wilder SP, Bihoreau MT, Cloarec O, Azzouzi I, Young S, Barton RH, Holmes E, McCarthy MI, Tatoud R, Nicholson JK, Scott J, Gauguier D.

Diabetologia. 2007 Sep;50(9):1867-79. Epub 2007 Jul 6.

PMID:
17618414
4.

Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action.

Wunderlich FT, Ströhle P, Könner AC, Gruber S, Tovar S, Brönneke HS, Juntti-Berggren L, Li LS, van Rooijen N, Libert C, Berggren PO, Brüning JC.

Cell Metab. 2010 Sep 8;12(3):237-49. doi: 10.1016/j.cmet.2010.06.011.

5.

Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.

Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE.

Am J Gastroenterol. 2008 Jun;103(6):1372-9. doi: 10.1111/j.1572-0241.2007.01774.x. Epub 2008 May 28.

PMID:
18510618
6.

Amelioration of diet-induced diabetes mellitus by removal of visceral fat.

Pitombo C, Araújo EP, De Souza CT, Pareja JC, Geloneze B, Velloso LA.

J Endocrinol. 2006 Dec;191(3):699-706.

7.

The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.

Cong WN, Tao RY, Tian JY, Liu GT, Ye F.

Life Sci. 2008 May 7;82(19-20):983-90. doi: 10.1016/j.lfs.2008.01.022. Epub 2008 Mar 4.

PMID:
18417155
8.

Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis.

Hashem RM, Mahmoud MF, El-Moselhy MA, Soliman HM.

Eur J Gastroenterol Hepatol. 2008 Oct;20(10):995-1001. doi: 10.1097/MEG.0b013e3282fdf65f.

PMID:
18787467
9.

Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling.

Qin B, Anderson RA, Adeli K.

Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1120-9. doi: 10.1152/ajpgi.00407.2007. Epub 2008 Mar 27.

10.

Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo.

Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK.

Diabetes. 2004 Apr;53(4):1060-7.

11.

Epidermal growth factor protects the liver against alcohol-induced injury and sensitization to bacterial lipopolysaccharide.

Deaciuc IV, D'Souza NB, Burikhanov R, Lee EY, Tarba CN, McClain CJ, de Villiers WJ.

Alcohol Clin Exp Res. 2002 Jun;26(6):864-74.

PMID:
12068256
12.

Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease.

Kathirvel E, Morgan K, French SW, Morgan TR.

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):973-83. doi: 10.1097/MEG.0b013e328328f461.

PMID:
19307976
13.

Reversion of steatosis by SREBP-1c antisense oligonucleotide did not improve hepatic insulin action in diet-induced obesity mice.

Vitto MF, Luz G, Luciano TF, Marques SO, Souza DR, Pinho RA, Lira FS, Cintra DE, De Souza CT.

Horm Metab Res. 2012 Nov;44(12):885-90. doi: 10.1055/s-0032-1321819. Epub 2012 Aug 29.

PMID:
22932913
14.

High-fat diets promote insulin resistance through cytokine gene expression in growing female rats.

Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT.

J Nutr Biochem. 2008 Aug;19(8):505-13. Epub 2007 Sep 27.

PMID:
17904344
15.

Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice.

Korsheninnikova E, van der Zon GC, Voshol PJ, Janssen GM, Havekes LM, Grefhorst A, Kuipers F, Reijngoud DJ, Romijn JA, Ouwens DM, Maassen JA.

Diabetologia. 2006 Dec;49(12):3049-57. Epub 2006 Sep 28.

PMID:
17006666
16.

Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone.

Leclercq IA, Lebrun VA, Stärkel P, Horsmans YJ.

Lab Invest. 2007 Jan;87(1):56-65. Epub 2006 Oct 30.

17.

Liver-specific deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice.

Simmgen M, Knauf C, Lopez M, Choudhury AI, Charalambous M, Cantley J, Bedford DC, Claret M, Iglesias MA, Heffron H, Cani PD, Vidal-Puig A, Burcelin R, Withers DJ.

Diabetologia. 2006 Mar;49(3):552-61. Epub 2006 Jan 11.

PMID:
16404553
18.

Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance.

Gutiérrez-Juárez R, Pocai A, Mulas C, Ono H, Bhanot S, Monia BP, Rossetti L.

J Clin Invest. 2006 Jun;116(6):1686-95.

19.

COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.

Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC.

Obesity (Silver Spring). 2009 Jun;17(6):1150-7. doi: 10.1038/oby.2008.674. Epub 2009 Feb 26.

20.

Supplemental Content

Support Center